⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
DYN
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
DYN
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
globenewswire.com
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
globenewswire.com
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
globenewswire.com
DYN
Form 8-K
sec.gov
DYN